Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02501096 · ClinicalTrials.gov registry record · Phase 1
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
A Phase 1 study of Tumors, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 357
- Enrollment target
- 20
- Study locations
NCT02501096: Completed Phase 1 study of Tumors, sponsored by Eisai.
NCT02501096 is a Phase 1 study of Tumors that has completed, run by Eisai. The registered enrollment target is 357 participants, above the 181-participant average among 20 other Tumors trials with a reported enrollment target (97% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02501096, a Phase 1 study of Tumors, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 357 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous \[IV\], every 3 weeks \[Q3W\]) pembrolizumab in participants with selected solid tumors (i.e. non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, melanoma or leiomyosarcoma). Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 7 cohorts at the MTD from Phase 1b (lenvatinib 20 mg/day orally + pembrolizumab 200 mg Q3W, IV).
Primary Outcome
MTD was confirmed if no more than 3 participants experience dose-limiting toxicities(DLTs)during first 3 weeks (Cycle 1) of treatment.If MTD was not confirmed at dose level,then enrollment was proceeded to next lower dose level.Sponsor and investigators reviewed all participants' safety;clinical data to jointly determine RP2D of combination of treatment.DLT may be any of following: hematological/nonhematological toxicities considered to be at least possibly related to Lenvatinib/pembrolizumab oc
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
Study Locations (20)
Colorado
- Rocky Mountain Cancer Centers - Aurora
- Rocky Mountain Cancer Centers - Boulder
- Rocky Mountain Cancer Centers - Colorado Springs
- Rocky Mountain Cancer Centers, Site #1 - Denver
- Rocky Mountain Cancer Centers, Site #2 - Denver
- Rocky Mountain Cancer Centers - Lakewood
- Rocky Mountain Cancer Centers - Littleton
- Rocky Mountain Cancer Centers - Lone Tree
- Rocky Mountain Cancer Centers - Longmont
- Rocky Mountain Cancer Centers - Parker
- Rocky Mountain Cancer Centers - Pueblo
- Rocky Mountain Cancer Centers - Thornton
Arizona
- Arizona Oncology Associates - Oro Valley
- Arizona Oncology Associates, PC - HOPE, Site #1 - Tucson
- Arizona Oncology Associates, PC - HOPE, Site #2 - Tucson
- Arizona Oncology Associates, PC - HOPE, Site #3 - Tucson
Florida
- Baptist Health Medical Group Oncology, LLC, Site #1 - Miami
- Baptist Health Medical Group Oncology, LLC, Site #2 - Miami
- Baptist Health Medical Group Oncology, LLC, Site #3 - Miami
Alaska
- Alaska Clinical Research Center - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2015-07-22 |
| Est. Completion | 2022-07-11 |
| Phase | Phase 1 |
What the finished NCT02501096 record still lists
NCT02501096 is an interventional study that assigns participants to a tested intervention. The registered 357 participants enrollment target is mid-sized for trials with a published cap, above the 181-participant average among 20 other Tumors trials with a reported enrollment target (97% higher).
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02501096 names 20 study sites across 4 states, led by Colorado, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT02501096 about?
NCT02501096 is a clinical study titled "A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors". This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous \[IV\], every 3 weeks \[Q3W\]) pembroli...
What is the current status of trial NCT02501096?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 357 participants. The study started on 2015-07-22. Estimated completion is 2022-07-11.
What conditions does trial NCT02501096 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT02501096?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT02501096?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02501096 being conducted?
This trial has 20 study locations across Alaska, Arizona, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02501096's enrollment target sits among peer trials
357 4th of 20 higher than 17 of 20 other Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062888 · 357 participants · Phase 2
FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial
- NCT06109766 · 357 participants · NA
Delivering Evidence-Based Parenting Services to Families in Child Welfare Using Telehealth
- NCT06231342 · 357 participants · NA
Endotracheal Tube (ETT) 180: Stylet-loaded Endotracheal Tube Rotation Before Insertion
- NCT06533826 · 357 participants · Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI